Brief: Metavia Inc - Announces Positive Ai-Modeling Results From Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets For Vanoglipel
04/02/2026 13:06
Feb 4 (Reuters) - SyntekaBio Inc 226330.KQ: METAVIA INC - ANNOUNCES POSITIVE AI-MODELING RESULTS FROM ONGOING SYNTEKABIO COLLABORATION, CONFIRMING KEY THERAPEUTIC TARGETS FOR VANOGLIPEL Source text: ID:nPn8G9Qy9a Further company coverage: 226330.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MetaVia
See all newsMetaVia Inc reports results for the quarter ended June 30 - Earnings Summary
MetaVia Q2 net loss widens on higher R&D spending
MetaVia Inc expected to post a loss of 82 cents a share - Earnings Preview
Brief: Biostem Technologies Announces Appointment Of Three New Members To Its Board Of Directors
MetaVia Q1 net loss widens slightly as expenses rise